The MHRA update is simply a reminder that powerful drugs require powerful vigilance, and until we have larger, long-duration real-world safety data, clinicians should err on the side of specificity in monitoring and patients should be taught exactly what to look for. Hector Perez, MD
Is vomiting from Wegovy dangerous
A thorough medical screening is absolutely essential to flag any potential risks ahead of time
But as someone who prescribes only legitimate GLP-1 therapies to people with obesity and weight-related metabolic diseases, I need to say this: Microdosing GLP-1s is not a thing
Quick Answer: No direct drug interaction between semaglutide and bupropion Lexicomp and Drugs.com interaction databases classify the combination as no known interaction with a minor note about additive appetite suppression
Over time, consuming fewer calories results in weight loss